Why Long-Term Maintenance Dose Selection Matters Most
2.4mg Wegovy vs Mounjaro: Fundamental Mechanism Differences
The 2.4mg Wegovy maintenance dose represents the maximum licensed strength of semaglutide, a selective GLP-1 receptor agonist that mimics your body's natural fullness hormone. This single-pathway approach has been extensively studied in the STEP trial programme, demonstrating sustained weight management when used alongside a reduced-calorie diet and increased physical activity. Mounjaro (tirzepatide) operates through dual GIP and GLP-1 receptor activation, offering a different mechanism that some prescribers prefer for specific patient profiles.
When comparing 2.4mg Wegovy against Mounjaro's dose range of 2.5mg to 15mg, the dosing philosophies differ significantly. Wegovy 2.4mg represents the endpoint of a structured 16-week escalation, designed for long-term maintenance, whilst Mounjaro continues dose increases up to 15mg based on individual response and tolerability. This fundamental difference affects both cost planning and treatment expectations for patients established on maintenance therapy.
Pricing Transparency for 2.4mg Wegovy vs Mounjaro Maintenance
At EverydayMeds, 2.4mg Wegovy costs £209.99 per pen, with returning customers applying code DOSE25 at checkout to access this pricing. For maintenance patients requiring consistent supply, our Consistency 2.4mg (×2) bundle provides two pens for £419.99, whilst the Ultimate Stability Trio offers three months of 2.4mg Wegovy for £649.99. This transparent pricing structure allows accurate monthly budgeting for long-term weight management commitment.
Mounjaro pricing varies across its six dose strengths, from 2.5mg starter doses through to 15mg maximum maintenance. Unlike 2.4mg Wegovy's fixed maintenance approach, Mounjaro patients may require ongoing dose adjustments, affecting monthly costs unpredictably. Both prescription-only medicines require clinical assessment and prescriber oversight, but the predictable nature of 2.4mg Wegovy maintenance provides clearer financial planning for sustained treatment.
Clinical Evidence Supporting 2.4mg Wegovy Maintenance
The STEP 5 trial specifically examined long-term maintenance with 2.4mg Wegovy, demonstrating sustained weight loss of approximately 15.2% at two years when combined with lifestyle interventions. This evidence directly supports the maintenance dose philosophy, showing that 2.4mg Wegovy can provide consistent benefits without requiring further dose escalation.
STEP 1 extension data revealed that patients regained approximately two-thirds of their weight loss within one year of discontinuing treatment, emphasising why maintenance therapy selection matters significantly. The 2.4mg Wegovy maintenance approach acknowledges that weight management requires long-term commitment, with treatment consistency being crucial for sustained outcomes.
How 2.4mg Wegovy Works in Maintenance Phase
As a GLP-1 receptor agonist, 2.4mg Wegovy works by binding to GLP-1 receptors in the brain, pancreas, and digestive system. This activation reduces appetite by affecting brain appetite centres, whilst promoting feelings of fullness after smaller meals and potentially reducing food cravings. The 2.4mg maintenance dose provides consistent GLP-1 receptor stimulation throughout each week, with the once-weekly injection maintaining therapeutic levels. During maintenance phase, this mechanism supports continued appetite regulation without the metabolic disruption of ongoing dose changes. The established 2.4mg strength has been optimised through clinical trials to provide maximum benefit whilst minimising the risk of dose-related side effects that might occur with further increases.
Streamlined Ordering Process for 2.4mg Wegovy
Ordering 2.4mg Wegovy from EverydayMeds begins with a 3-minute online clinical assessment, designed specifically for maintenance patients who understand their treatment requirements. Our prescribers review applications within 3 working days as standard, with express 24-hour review available for treatment continuity needs. Once approved, your 2.4mg Wegovy ships via next-day delivery using cold-chain temperature-controlled packaging to maintain medication integrity. For maintenance patients, our repeat prescription service ensures seamless reordering without repeating full assessments each month. This efficient process recognises that 2.4mg Wegovy maintenance patients require reliable, consistent supply rather than complex clinical reassessment at every order.
Storage and Practical Advantages of 2.4mg Wegovy
2.4mg Wegovy requires refrigeration at 2-8°C before first use but maintains potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration. This storage flexibility provides significant advantages over Mounjaro's 21-day room temperature limit, particularly important for maintenance patients who travel frequently or experience refrigeration issues. The FlexTouch pen design delivers precise 2.4mg doses with clear dose confirmation, whilst the established maintenance dosing eliminates ongoing titration complexity. For long-term users, this storage advantage and dosing simplicity reduces treatment burden compared to alternatives requiring stricter storage conditions or ongoing dose adjustments. The 6-week room temperature stability makes 2.4mg Wegovy particularly suitable for patients requiring consistent, reliable maintenance therapy without storage anxiety.
2.4mg Wegovy vs Mounjaro: Maintenance Strategy Comparison
The 2.4mg Wegovy maintenance approach reflects a "find effective dose and maintain" philosophy, supported by clinical evidence showing sustained benefits at this strength. This contrasts with Mounjaro's "optimise upward as needed" approach, where patients may continue dose escalation beyond equivalent GLP-1 activity levels. For maintenance patients, 2.4mg Wegovy offers predictability in both effects and costs, crucial factors for long-term treatment commitment.
Treatment interruption and restart protocols also differ between 2.4mg Wegovy and Mounjaro maintenance regimens. Wegovy's established maintenance dose allows more straightforward treatment resumption, whilst Mounjaro may require re-titration depending on interruption duration and previous dose achieved. This practical consideration becomes significant for maintenance patients managing treatment alongside life events, travel, or other health priorities requiring temporary treatment modifications.
Making Your 2.4mg Wegovy vs Mounjaro Decision
EverydayMeds stocks both 2.4mg Wegovy and all Mounjaro strengths, ensuring your prescriber can select the most appropriate option based on your individual clinical profile and maintenance requirements. Our clinical team, operating under GPhC registration #9012878, provides expert assessment regardless of which prescription-only medicine suits your needs. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment, using code DOSE25 if you're an existing patient or FIRST40 for new customers at checkout. Both treatments require ongoing commitment alongside reduced-calorie diet and increased physical activity, but our expert team ensures you receive the right maintenance therapy for your long-term weight management journey. Remember that treatment selection should always prioritise clinical appropriateness over cost considerations, though our transparent pricing supports informed decision-making throughout your maintenance phase.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
